4.5 Article

Tenomodulin variants, APOE and Alzheimer's disease in a Finnish case-control cohort

Journal

NEUROBIOLOGY OF AGING
Volume 32, Issue 3, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2009.05.010

Keywords

Alzheimer's disease; Apolipoprotein E; Genetic risk factors; Tenomodulin

Funding

  1. Health Research Council of the Academy of Finland
  2. Kuopio University Hospital [5772708, 5254]
  3. Finnish Funding Agency for Technology and Innovation [40058/07]
  4. Biocenter Kuopio
  5. Sigrid Juselius Foundation
  6. Nordic Center of Excellence on 'Neurodegenerative Diseases' and 'Systems biology in controlled dietary interventions and cohort studies (SYSDIET)'

Ask authors/readers for more resources

The tenomodulin gene (TNMD, locus Xq-22) encodes an angiogenesis inhibitor. It is an interesting candidate gene for Alzheimer's disease (AD), since it is expressed in brain, alterations in angiogenesis have been linked to AD and in our previous studies we have observed associations between TNMD and phenotypes, which are related to increased risk of AD. The common sequence variation in the TNMD was not associated with prevalence of AD among 526 cases and 672 controls. However, a significant interaction (p = 0.002) between rs5966709 and the APOE epsilon 4-allele status was observed in women. Among the e4-allele carriers, the women with rs5966709-TT genotype had smaller risk for having AD than those with other genotypes (odds ratio 0.47, p = 0.019, false discovery rate 10.4%). According to these results the sequence variation of TNMD is not associated with AD, but might modify the effect of APOE e4-allele in women. (C) 2009 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available